ENDOTHELION Study Group: Effect of Bosentan in NAION Patients
Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
Acute ischemic optic neuropathy are the second leading cause of optic neuropathy after
glaucoma in the population aged over 50 years. The visual prognosis of the condition is
unfavorable in the great majority of cases, with significant effects on the visual field and
vision. The severity of the unilateral condition is also associated with bilateralization in
15% at 5 years. There is no effective treatment for the acute phase of the disease or to
reduce the rate of bilateralization. In this context, it is essential to develop new
therapeutic strategies in the acute phase of the disease to reduce the anatomical optic nerve
damage.